Aug 27, 2026

AstraZeneca (AZN) Stock Slides Despite Positive Tezspire Trial Results

AstraZeneca (AZN) stock declined 2% after positive Tezspire trial results. Pipeline setbacks weigh on shares despite analyst price targets showing 33% upside.

The post AstraZeneca (AZN) Stock Slides Despite Positive Tezspire Trial Results appeared first on Blockonomi.

Source: Blockonomi →

AstraZeneca (AZN) Stock Slides Despite Positive Tezspire Trial Results

Related News

Paramount Settlement Sends WBD Stock Sharply Higher

NFLX Stock Drops After Wells Fargo Warning

NBIS Stock Jumps 5.6% as AI Pricing Boosts Momentum

T-Mobile US (TMUS) Stock: New Jio Partnership Advances Global 5G Roaming

Semtech Corporation (SMTC) Stock: New 50G Technology Supports 6G Transition

Trending Category

Latest News

BitMine ETH Treasury Nears 6 Million Tokens As Total Holdings Reach $17.1B

Strive Adds 1,355 Bitcoin As Corporate Treasury Reaches 26,355 BTC

Google Admits Gemini AI Hacked Three Companies—It Stayed Silent for 7 Weeks

Strategy Buys Another 950 Bitcoin As Holdings Reach 846,000 BTC

After Clarity Act Fails, Crypto Super PAC Fairshake Targets Sherrod Brown With $...

Robinhood CEO Says Crypto Will Beat Sports at Prediction Markets' Own Game

Bitcoin Reclaims $85,000 For First Time In Eight Months

Bitcoin News: How High Can BTC Go After Hitting $87000?

Bitcoin could test $90,000 after shorts get squeezed, but traders warn leverage...

Saudi Arabia exits China-backed mBridge CBDC project: FT

Legal

Crypto News

AstraZeneca (AZN) Stock Slides Despite Positive Tezspire Trial Results

Related News

Trending Category

Latest News